{"product_id":"genmab-swot-analysis","title":"Genmab SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGenmab’s cutting-edge antibody platforms, strong partner network, and robust late-stage pipeline position it well for sustained growth, though patent cliffs, competition, and regulatory risks warrant careful monitoring; curious how these factors translate to valuation and strategy? Purchase the full SWOT analysis to access a professionally written, editable report and Excel matrix—ideal for investors, advisors, and strategists seeking actionable, research-backed insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Antibody Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab’s proprietary platforms—DuoBody, HexaBody, and DuoHexaBody—drive differentiated therapeutics, enabling bispecifics that bind two receptors for precision targeting and improved efficacy.\u003c\/p\u003e\n\u003cp\u003eThese platforms powered multiple candidates into late-stage trials by end-2025, including at least three Phase 3 programs, demonstrating clinical scalability and lowering development risk.\u003c\/p\u003e\n\u003cp\u003ePlatform licensing and collaborations generated over $900m in revenue-related milestones and royalties in 2024–25, reinforcing a strong commercial moat and funding R\u0026amp;D expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Royalty Stream from Darzalex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab earns a steady, high-margin royalty stream from Janssen’s Darzalex (daratumumab), which generated Janssen global sales of about $6.9 billion in 2024 and sustained ~30% market share in multiple myeloma by late 2025, per company reports.\u003c\/p\u003e\n\u003cp\u003eThose royalties funded Genmab’s R\u0026amp;D cushion—Genmab reported €1.1 billion cash and equivalents at end-2024—letting it progress antibody programs without sole reliance on capital markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic High-Value Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab has deep partnerships with AbbVie, Pfizer, and BioNTech, giving it access to global commercial networks while keeping double-digit to mid-teen royalty or profit-share stakes (e.g., Roche\/Genmab-like deals historically range 10–20%).\u003c\/p\u003e\n\u003cp\u003eThis co-development model shares clinical and regulatory costs—Genmab reported partnering revenue of DKK 3.6bn in 2024—so development risk and capex burden shrink while upside stays material.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep and Diversified Oncology Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab holds a broad oncology portfolio across hematologic malignancies and solid tumors, lowering reliance on any single asset and reducing binary risk.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Epkinly (epcoritamab) and Tivdak (tisotumab vedotin) secured additional indications, helping Genmab shift to a multi-asset commercial company with recurring revenue streams; 2025 guidance targeted product revenues \u0026gt;€1.2bn combined.\u003c\/p\u003e\n\u003cp\u003eThis diversification stabilizes long-term valuation: one failed trial now impacts a fraction of assets and cash-flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWide portfolio: hematologic + solid tumors\u003c\/li\u003e\n\u003cli\u003eEpkinly + Tivdak additional indications in 2025\u003c\/li\u003e\n\u003cli\u003e2025 product revenue \u0026gt;€1.2bn (combined)\u003c\/li\u003e\n\u003cli\u003eLower single-asset binary risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Cash Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab held €2.3bn in cash and equivalents at end-2024, giving a fortress balance sheet that funds R\u0026amp;D and M\u0026amp;A without near-term dilution.\u003c\/p\u003e\n\u003cp\u003eThis liquidity lets Genmab invest in its proprietary pipeline and pursue bolt-on acquisitions of smaller biotechs or novel platforms.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, this financial strength should set Genmab apart from peers facing funding pressure in a choppy market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€2.3bn cash (end-2024)\u003c\/li\u003e\n\u003cli\u003eSupports pipeline funding + opportunistic M\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eCompetitive edge vs. cash-strapped peers by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab’s platforms drive €900m+ royalties, €2.3bn cash and \u0026gt;€1.2bn 2025 revenue outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab’s proprietary platforms (DuoBody\/HexaBody\/DuoHexaBody) power multiple late‑stage bispecifics, lowering development risk; platform deals and royalties generated \u0026gt;€900m in 2024–25. Steady Darzalex royalties (Janssen sales ~€6.4bn in 2024) and €2.3bn cash (end‑2024) fund R\u0026amp;D and M\u0026amp;A, supporting \u0026gt;€1.2bn product revenue guidance for 2025 and diversified oncology portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform revenues (2024–25)\u003c\/td\u003e\n\u003ctd\u003e€900m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex sales (Janssen, 2024)\u003c\/td\u003e\n\u003ctd\u003e~€6.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (end‑2024)\u003c\/td\u003e\n\u003ctd\u003e€2.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 product revenue guidance\u003c\/td\u003e\n\u003ctd\u003e€1.2bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Genmab, highlighting its core strengths in antibody platforms and pipeline assets, key weaknesses such as dependency on partner revenues, growth opportunities from expanding oncology indications and geographic markets, and external threats including competitive biologics, pricing pressures, and regulatory risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Genmab SWOT matrix for rapid strategic alignment, ideal for executives and teams needing a clear snapshot of strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Revenue Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 60% of Genmab’s 2024 revenue came from Janssen royalties on Darzalex, concentrating earnings in one product and raising single-drug risk.\u003c\/p\u003e\n\u003cp\u003eRegulatory moves, safety issues, or new competitors in multiple myeloma could cut royalties quickly; a 10% market-share loss would trim total revenue by ~6 percentage points.\u003c\/p\u003e\n\u003cp\u003eWith primary Darzalex patents facing expiry in the late 2020s, investors worry about sustainability and potential revenue decline without newer commercialized assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Research and Development Intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining a cutting-edge position forces Genmab to spend heavily on R and D, compressing gross margins; R and D expenses rose to DKK 5.1 billion in 2024 and management guided elevated spend into 2025. Late-stage trials for multiple proprietary assets pushed operational cash burn to about DKK 3.2 billion H1 2025, increasing financing needs. These costs create earnings volatility and can depress the stock during clinical setbacks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Partner Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab relies heavily on partners such as Janssen and AbbVie to commercialize its top products, leaving the company limited control over sales tactics and market execution.\u003c\/p\u003e\n\u003cp\u003eIf a partner re-prioritizes—Janssen cut R\u0026amp;D headcount by 4% in 2024—Genmab’s royalty and milestone streams (2024 revenue: DKK 12.3bn; partner-derived ~85%) could face downside.\u003c\/p\u003e\n\u003cp\u003eThis lack of full commercial autonomy constrains Genmab’s ability to maximize peak market share and pricing for shared assets, especially in competitive oncology markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Manufacturing Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe production of genmab bispecific and hexameric antibodies is highly technical needing specialized cgmp facilities that can cost tens to hundreds millions build\u003e$30M\/yr to operate; any manufacturing failure could trigger supply shortfalls and regulatory fines. \n\u003cpas genmab advances multiple candidates toward commercialization managing a global cold-chain and contract manufacturing network raises logistical risk increases potential for costly delays.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh fixed costs: facility builds $50–200M\u003c\/li\u003e\n\u003cli\u003eOperating spend: \u0026gt;$30M\/year typical\u003c\/li\u003e\n\u003cli\u003eSupply risk: single-point failures cause multi-month shortages\u003c\/li\u003e\n\u003cli\u003eCommercial scale-up pressure by 2025 adds complexity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pas\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Legal and Arbitration Disputes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab has faced prolonged legal battles and arbitrations with Janssen over royalties and IP, most notably disputes that affected royalty receipts through 2024 and generated legal costs exceeding DKK 200m in some years.\u003c\/p\u003e\n\u003cp\u003eThese conflicts create cash-flow and forecasting uncertainty for shareholders and risk eroding future milestone and royalty income streams tied to partnered products.\u003c\/p\u003e\n\u003cp\u003eThe recurrence of partner friction points to weaknesses in contract management and long-term relationship stability, raising governance concerns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtracted Janssen disputes\u003c\/li\u003e\n\u003cli\u003eLegal costs \u0026gt; DKK 200m in years\u003c\/li\u003e\n\u003cli\u003eRoyalties and milestone volatility\u003c\/li\u003e\n\u003cli\u003eContract-management vulnerability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDarzalex dependency, heavy R\u0026amp;D burn and legal risks threaten revenue cliff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue concentrated: ~60% of 2024 sales from Janssen Darzalex royalties (2024 revenue DKK 12.3bn); patent expiries late 2020s risk sharp declines. High R\u0026amp;D burn (DKK 5.1bn in 2024; H1 2025 cash burn ~DKK 3.2bn) compresses margins. Partner dependence (~85% 2024 partner-derived revenue) and repeated Janssen disputes (legal costs \u0026gt;DKK 200m) create forecast volatility. Manufacturing scale-up needs \u0026gt;$30M\/yr, high capex.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (DKK)\u003c\/td\u003e\n\u003ctd\u003e12.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e5.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 cash burn\u003c\/td\u003e\n\u003ctd\u003e~3.2bn (H1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner revenue\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal cost years\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;DKK 200m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing op-ex\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$30M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGenmab SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752412983673,"sku":"genmab-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/genmab-swot-analysis.png?v=1772240695","url":"https:\/\/matrixbcg.com\/products\/genmab-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}